Year: 2021
Type: article
Abstract: ultiple myeloma remains an incurable disease and a new perspective on the approach to therapy is required.Adhesion of multiple myeloma cells to bone marrow stromal cells initiates secretion of soluble factors like interleukin-6 and tumour necrosis factor-α, resulting in activation of intracellular, anti-apoptotic signalling pathways.These pathways confer protection to myeloma cells by upregulating expression of anti-apoptotic proteins like MCL-1, BCL-2 and BCL-XL, as well as providing protection against FAS-mediated apoptosis.These anti-apoptotic proteins and survival pathways provide a framework for the design of therapeutic drugs.The development of such biologically based treatments that target BCL-2 proteins and MDM-2-P53 pathway have shown promising results and may ultimately lead to improved survival, slower disease progression in multiple myeloma and increased sensitivity to other drugs.
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3194049570